null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Enoblituzumab Biosimilar (Anti-B7-H3) Antibody (HDBS0010)

SKU HDBS0010
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer Immunotherapy
Disease Area Tumor Microenvironment
Protein B7-H3
Reactivity Human
Host Species Humanized
Isotype IgG1
€431
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Enoblituzumab (Anti-B7-H3) Biosimilar Antibody (HDBS0010)

The Anti-B7-H3 (Enoblituzumab) Biosimilar Antibody (MAB-HDBS0010) is a monoclonal antibody developed for research purposes targeting the B7-H3 protein, a cell surface molecule that plays a vital role in immune regulation and tumor immunity. This biosimilar antibody, derived from Enoblituzumab, binds specifically to the B7-H3 protein, allowing for accurate detection and characterization in various cell types.The B7-H3 protein has been identified as a promising target for cancer immunotherapy due to its role in immune checkpoint regulation and tumor progression.

By targeting B7-H3, researchers can further investigate its function in cancer development and explore potential therapeutic strategies for cancer treatment.This high-quality biosimilar antibody is suitable for a wide range of research applications, including Western blotting, immunohistochemistry, and flow cytometry. Its specificity and sensitivity make it a valuable tool for studying the biological functions of B7-H3 and its potential as a therapeutic target in cancer research.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose